N. Schleucher

2.1k citations

32 papers · 1.6k indexed · 1 hit paper · h-index 19

Impact in

Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 19
- Colorectal Cancer Treatments and Studies 12
- Cancer Treatment and Pharmacology 9
- Lung Cancer Research Studies 3
Hematology 6
- Multiple Myeloma Research and Treatments 5

Co-authors: S. Seeber Mitra Tewes U. Vanhoefer Ralf A. Hilger Heike Richly E. Brendel D. Voliotis M. E. Scheulen
Journals: Journal of Clinical Oncology (13 papers)British Journal of Cancer (4 papers)European Journal of Cancer (4 papers)Annals of Oncology (4 papers)Anti-Cancer Drugs (2 papers)
Partner nations: Germany United States Belgium

In The Last Decade

N. Schleucher

31 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors 2004 · 694 citations

Peers

Countries citing papers authored by N. Schleucher

Since Specialization

Citations

This map shows the geographic impact of N. Schleucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Schleucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Schleucher more than expected).

Fields of papers citing papers by N. Schleucher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Schleucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Schleucher. The network helps show where N. Schleucher may publish in the future.

Co-authors

The 25 scholars most cited alongside N. Schleucher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with N. Schleucher Line = papers co-authored together N. Schleucher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas Investigational New Drugs ·Tanja Trarbach, Marta Przyborek, N. Schleucher, S. Heeger, Christian Lüpfert, U. Vanhoefer	2012	13
2	Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO Annals of Oncology ·Christian Kollmannsberger, Wilfried Budach, M. Stahl, N. Schleucher, Thomas Hehr, H. Wilke, Jan Schleicher, U. Vanhoefer, E. C. Jehle, Karin Oechsle, Tanja Trarbach, I. Boehlke, Lothar Kanz, J.T. Hartmann, Carsten Bokemeyer	2005	31
3	A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Annals of Oncology ·K. Mross, Heike Richly, N. Schleucher, S. Korfee, Mitra Tewes, M. E. Scheulen, S. Seeber, T. Beinert, Michael Schweigert, Uwe Sauer, Clemens Unger, Dirk Behringer, E. Brendel, Catherine G. Haase, D. Voliotis, Dirk Strumberg	2004	21
4	Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer Journal of Cancer Research and Clinical Oncology ·Jan Wierecky, Christian Kollmannsberger, I. Boehlke, M.A. Kuczyk, Jan Schleicher, N. Schleucher, Bernd Metzner, Lothar Kanz, Jakob Hartmann, Carsten Bokemeyer	2004	32
5	A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers Journal of Clinical Oncology ·Tanja Trarbach, Thomas Beyer, N. Schleucher, J. Stattaus, Stefan Müeller, D. Appel, J. Tillner, K. W. Schmid, S. Seeber, U. Vanhoefer	2004	11
6	A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers Journal of Clinical Oncology ·Tanja Trarbach, Thomas Beyer, N. Schleucher, J. Stattaus, Stefan Müeller, D. Appel, J. Tillner, K. W. Schmid, S. Seeber, U. Vanhoefer	2004	4
7	Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer Journal of Clinical Oncology ·N. Schleucher, Tanja Trarbach, U. Junker, Mitra Tewes, Eric Masson, David Lebwohl, S. Seeber, Dirk Laurent, U. Vanhoefer	2004	10
8	Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support European Journal of Cancer ·Christian Kollmannsberger, N. Schleucher, Oliver Rick, Bernd Metzner, Jakob Hartmann, Patrick Schöffski, J. Beyer, J. Casper, Markus Sosada, Hans‐Joachim Schmoll, I. Böhlke, Christoph Meisner, Lothar Kanz, Carsten Bokemeyer	2003	4
9	Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study† Annals of Oncology ·Mitra Tewes, N. Schleucher, W. Achterrath, Hans‐Joachim Wilke, S. Frings, S. Seeber, A. Harstrick, Youcef M. Rustum, U. Vanhoefer	2003	46
10	First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial British Journal of Cancer ·Carsten Bokemeyer, N. Schleucher, Bernd Metzner, Michaël Thomas, Oliver Rick, Hans‐Joachim Schmoll, Christian Kollmannsberger, I. Boehlke, Lothar Kanz, J.T. Hartmann	2003	30
11	Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group Journal of Clinical Oncology ·Hans‐Joachim Schmoll, Christian Kollmannsberger, Bernd Metzner, J.T. Hartmann, N. Schleucher, Patrick Schöffski, Jan Schleicher, Oliver Rick, J. Beyer, D Hossfeld, Lothar Kanz, Wolfgang E. Berdel, R. Andreesen, Carsten Bokemeyer	2003	99
12	Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor Journal of Clinical Oncology ·U. Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, N. Schleucher, Oliver Rosen, J. Tillner, Andreas Kovar, Ada Braun, Tanja Trarbach, S. Seeber, A. Harstrick, José Baselga	2003	221
13	Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer British Journal of Cancer ·Carsten Bokemeyer, Karin Oechsle, Jakob Hartmann, Patrick Schöffski, N. Schleucher, Bernd Metzner, Jan Schleicher, Lothar Kanz	2002	26
14	First-line high-dose chemotherapy ± radiation therapy in patients with metastatic germ-cell cancer and brain metastases Annals of Oncology ·Christian Kollmannsberger, Craig R. Nichols, M. Bamberg, J.T. Hartmann, N. Schleucher, J. Beyer, P. Schöffski, G. Derigs, U. Rüther, I. Böhlke, Hans‐Joachim Schmoll, Lothar Kanz, Carsten Bokemeyer	2000	41
15	Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer Anti-Cancer Drugs ·Christian Kollmannsberger, A. Gerl, N. Schleucher, J. Beyer, Markus A. Kuczyk, Oliver Rick, Jochen Casper, Markus Sosada, Christoph Rie, Lothar Kanz, Carsten Bokemeyer	2000	19
16	Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines British Journal of Cancer ·U. Vanhoefer, M. R. Müller, Ralf A. Hilger, Beate Lindtner, U. Klaassen, N. Schleucher, Youcef M. Rustum, S. Seeber, A. Harstrick	1999	21
17	Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance Anti-Cancer Drugs ·A. Harstrick, Andrea J. Gonzales, N. Schleucher, U. Vanhoefer, Kun Lu, J-L Formento, G. Milano, H. Wilke, S. Seeber, Youcef M. Rustum	1998	25
18	Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines British Journal of Cancer ·U. Klaassen, A. Harstrick, N. Schleucher, U. Vanhoefer, J Schröder, H. Wilke, S. Seeber	1996	19
19	Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell Lines in vitro European Journal of Cancer ·U. Vanhoefer, A. Harstrick, H. Wilke, N. Schleucher, Heike Walles, J Schröder, S. Seeber	1995	52
20	126 Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidilate synthase inhibitor tomudex (D1694) European Journal of Cancer ·A. Harstrick, N. Schleucher, Andrea J. Gonzales, C. G. Schmidt, A Hoffmann, H. Wilke, Y M Rustum, S. Seeber	1995	6

About N. Schleucher

N. Schleucher is a scholar working on Oncology, Hematology, Pulmonary and Respiratory Medicine, Gastroenterology and Pathology and Forensic Medicine, having authored 32 papers that have together received 1.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (10 papers), Cancer Treatment and Pharmacology (9 papers), Testicular diseases and treatments (9 papers), Cancer therapeutics and mechanisms (6 papers), Multiple Myeloma Research and Treatments (5 papers), Metastasis and carcinoma case studies (4 papers) and Lung Cancer Research Studies (3 papers). The work is most often cited by research in Oncology (802 citations), Hepatology (172 citations), Pulmonary and Respiratory Medicine (610 citations), Hematology (161 citations) and Reproductive Medicine (110 citations). N. Schleucher has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include S. Seeber, Mitra Tewes, U. Vanhoefer, Ralf A. Hilger, Heike Richly, E. Brendel, D. Voliotis, M. E. Scheulen, Dirk Strumberg and Markus Faghih. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer, Annals of Oncology and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact